EMAIL THIS PAGE TO A FRIEND

Oncotarget

The


PMID 29152138

Abstract

First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembrane transporters. However, the impact of transporters genes polymorphisms in nilotinib setting is still debated. We investigated the possible correlation between single nucleotide polymorphisms of

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

CDS023093
Nilotinib
C28H22F3N7O